Objective To investigate the technical outline and clinical value of percutaneons transhepatic portal vein port-catheter system implantation in preventing small hepatocellular carcinoma recurrence after curative treatments. Methods Fifteen patients with small hepatocellular carcinoma after curative treatment were included in this study. Guided by ultrasound and fluoroscopy, left branch of the portal vein were punctured and port-catheter system were implanted. Then drugs infusion into portal vein system was done for preventing recurrence of hepatic carcinoma. Results Interventional operations were succeed in all 15 cases. Drugs could drop into portal vein smoothly. No operating complications occurred. Conclusion Percutaneous transhepatic portal vein port-catheter system implantation was an easy operating and micro traumatic method. This technique could play an important role in preventing recurrence.
Key words:
Liver neoplasms; Chemotherapy, cancer, regional perfusion; Infusion pumps, implantable
Abstract Background: This research aimed to investigate the potential molecular mechanism of sorafenib resistance to hepatocellular carcinoma (HCC). Methods: Differential expression analysis were performed to identified differentially expressed genes (DEGs) in sorafenib resistant HCC. Then, a series of bioinformatic analysis were performed to explore the potential crucial molecules in sorafenib resistant HCC. For example, gene function annotation, pivot regulators prediction, ROC analysis and survival analysis. Results: There were 827 differentially expressed genes were identified. Moreover, most of the differentially expressed genes are involved in immune and inflammatory-related functions and signaling pathways. Also, 18 transcription factors were predicted to regulate the transcription factors of differentially expressed genes, which play an essential role in the regulation of dysfunctional gene networks. In target genes of transcription factors, CDK1 and CDKN1A have high diagnostic value in the resistance of hepatocellular carcinoma to sorafenib. Conclusions: TAPBP has the strongest correlation with drug resistance of hepatocellular carcinoma and the highest diagnostic efficiency. In addition, CDK1 and CDKN1A have high diagnostic value in the resistance of hepatocellular carcinoma to sorafenib. Overall, our analysis shows that a large number of gene disorders occur during the development of resistance to sorafenib in hepatocellular carcinoma, and they are associated with immune and inflammatory reactions in the body. These results provide critical theoretical references for the pathogenesis and diagnosis of sorafenib resistance.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
